Dear Colleagues,

Recent years have witnessed unprecedented progresses and innovations in personalized therapy in a move towards tailored interventions according to individual patients’ specific disease.

Following the WHO 2016 classification several new and emerging/provisional renal entities have been described. Immunotherapy has entered current practice in the metastatic setting, and has recently also seen use in the adjuvant setting for high-risk disease, but predictive markers are still lacking.

Antibody–drug conjugates are promising tools in bladder cancer, and are being tested in both neoadjuvant and advanced settings, with potential clinical value also in non-muscle invasive disease. Treatment selection and sequencing are still matters of debate, along with cost-efficiency issues.

In prostate cancer, cutting-edge methods such as artificial intelligence and computational pathology have demonstrated potential improvements in grading reproducibility and pattern quantification. Radiomics is a promising tool to detect and categorize prostate lesions by the quantitative extraction and analysis of data from medical images, being able to predict Gleason score and biochemical recurrence. PSMA-targeted imaging agents and different PSMA target therapies have been developed in parallel with molecular targeted drugs such PARP inhibitors and second-generation antiandrogens.

This Special Issue will provide a forum for the discussion of the most recent advanced topics in uro-oncology, with a special focus on biomarker investigation, new technological applications and therapeutic developments.

Dr. Alessia Cimadamore
Prof. Dr. Rodolfo Montironi
Prof. Dr. Antonio Lopez-beltran
Prof. Dr. Liang Cheng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• renal cell carcinoma
• bladder cancer
• prostate cancer
• targeted therapy
• radiomics
• artificial intelligence
• biomarkers